



**Bausch + Lomb and Technolas™ Perfect Vision  
Receive 510(k) FDA Clearance from FDA for  
VICTUS™ Femtosecond Laser Platform**

***First Single-Platform Femtosecond Laser Designed for  
Cataract and Corneal Surgery***

FOR RELEASE MONDAY, AUGUST 6, 2012

ALISO VIEJO, CA & MUNICH, GERMANY — Bausch + Lomb, the global eye health company, and *Technolas*™ Perfect Vision GmbH (TPV), a leading ophthalmology laser company, announced today that the *VICTUS*™ Femtosecond Laser Platform received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The *VICTUS* platform is the first femtosecond laser capable of supporting cataract and corneal procedures on a single platform. The versatile system is designed to provide greater precision compared to manual cataract surgery techniques, potentially enhancing patient experience.

The two companies plan to immediately introduce and begin placing the *VICTUS* platform at leading surgery centers in the U.S. Together, Bausch + Lomb and TPV promote the *VICTUS* platform globally, leveraging their combined cataract and refractive expertise and commercial capabilities. The *VICTUS* platform received CE mark approval in Europe in November of 2011 and has been used in more than two thousand cataract or refractive procedures around the world. The two organizations are working to gain approval for additional applications in the U.S. to maximize use of all of the unique capabilities of the *VICTUS* laser in cataract and refractive procedures.

"The introduction of femtosecond laser technology is the most significant advancement in cataract surgery in recent history," said Steven J. Dell, M.D. of Dell Laser Consultants in Austin, Texas. "Cataract surgery, in its traditional form, delivers excellent results, and is arguably one of the safest and most successful surgical procedures performed anywhere in the body. The opportunity to further improve the outcomes of cataract surgery is something I am proud to be a part of. With its U.S. clearance, the *VICTUS* platform will offer unique advantages for both cataract and corneal procedures to surgeons and patients."

"The *VICTUS* platform represents a major advancement for ophthalmic surgeons that can potentially enhance patient outcomes," said Kristian Hohla, Ph.D., chief executive officer of *Technolas* Perfect Vision. "We are committed to playing a leadership role in advancing femtosecond laser technology by working with customers, ophthalmic industry leaders and professional societies, alike. We look forward to the continued commercialization of the technology around the world, so that ophthalmic surgeons can experience its potential for themselves."

"Our pioneering research and development partnership with TPV has delivered innovation in laser surgery that allows us to offer a broader suite of ophthalmic surgical products and expand the global reach of this exciting new technology," said John Barr, executive vice president and president, global Surgical business for Bausch + Lomb. "Since signing a definitive agreement with an option to purchase TPV last September, the two organizations have made substantial technical and commercial progress in the field of advanced refractive and cataract technologies. This FDA clearance further strengthens our

relationship with TPV and we look forward to bringing the power of the *VICTUS* femtosecond laser to the U.S.”

While current cataract surgery techniques achieve positive outcomes, the procedure relies on multiple manual steps, which creates variability. Early published data suggest that Laser Refractive Cataract Surgery (LRCS), as offered by the *VICTUS* platform, may allow physicians to create a more precise, controllable and centered capsulotomy (an incision in the capsular bag that allows access to the cataract-clouded natural lens). LRCS may require less phaco energy and time during lens fragmentation, improve intraocular lens placement, and potentially enhance patient outcomes and experience.<sup>1-3</sup>

The *VICTUS* platform is cleared for creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea and anterior capsulotomy during cataract surgery, with plans to submit additional indications to the FDA. The product is now available for shipment in the U.S.

### **About Cataract Surgery**

An estimated 20 million aging baby boomers and seniors have cataracts. Over 15 million cataract surgeries are performed worldwide each year. A cataract is a clouding of the normally clear lens in the eye. Cataract surgery is a simple procedure during which the natural lens in the patient's eye is surgically replaced with an intraocular lens.

### **About Femtosecond Lasers**

Femtosecond lasers emit optical pulses of extremely short duration in the domain of femtoseconds, as short as one-quadrillionth of a second. These ultra-short pulses do not transfer heat or shock to the material being cut and can make surgical incisions with extreme precision. The technology was developed in the early 1990s at the University of Michigan Engineering Center. The first commercial platform was introduced in 2002 and the original approval was for flap creation during LASIK surgery. Recent platform approvals have been expanded to include additional corneal/therapeutic procedures and cataract applications.

### **About Technolas Perfect Vision**

*Technolas Perfect Vision GmbH (TPV)* is a leading ophthalmology laser company, formed through a joint venture between Bausch + Lomb, and 20/10 Perfect Vision AG. TPV has a full range of expertise in both femtosecond and excimer businesses. Current innovations focus on laser cataract surgery and the correction of presbyopia with the *SUPRACOR™* laser treatment. More information is available at [www.technolaspv.com](http://www.technolaspv.com) and [www.better-reading-vision.net](http://www.better-reading-vision.net).

### **About Bausch + Lomb**

Bausch + Lomb is one of the best-known and most respected healthcare companies in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, NY, and employs roughly 11,000 people worldwide. Its products are available in more than 100 countries. More information is available at [www.bausch.com](http://www.bausch.com).

### **REFERENCES**

1. Nagy Z, et al. Comparative analysis of femtolaser-assisted and manual capsularhexis during phacoemulsification. Presented at: XXVIII Congress of the European Society of Cataract and Refractive Surgeons; September 5, 2010; Paris, France.
2. Koch D, et al. The use of OCT-guided femtosecond laser to facilitate cataract nuclear disassembly and aspiration. Presented at: XXVIII Congress of the European Society of Cataract and Refractive Surgeons; September 5, 2010; Paris, France.

3. Batlle J, et al. Prospective randomized study of size and shape accuracy of OptiMedica femtosecond laser capsulotomy vs. manual capsularhexis. Presented at: XXVIII Congress of the European Society of Cataract and Refractive Surgeons; September 5, 2010; Paris, France.

*VICTUS* is a trademark of Bausch & Lomb Incorporated or its affiliates.

*TECHNOLAS* and TPV are trademarks of TPV Perfect Vision GmbH.

© 2012 Bausch & Lomb Incorporated.

# # #

**News Media Contacts:**

Jeanie Herbert

Global Surgical Communications, Bausch + Lomb

(949) 521-7948, (714) 325-3584 (mobile) or [jeanie.herbert@bausch.com](mailto:jeanie.herbert@bausch.com)

Elizabeth Murphy

Global Communications, Bausch + Lomb

(585) 338-8528 or [elizabeth.murphy@bausch.com](mailto:elizabeth.murphy@bausch.com)

Tad Heitmann

BioComm Network on behalf of Bausch + Lomb

(714) 273-2937 or [theitmann@BioCommNetwork.com](mailto:theitmann@BioCommNetwork.com)